Learn how HER2DX^® can help you apply precision oncology in your clinical practice

Redefining precision oncology

Unlocking the full potential of patient information

[data-wf-bgvideo-fallback-img] { display: none; } @media (prefers-reduced-motion: reduce) { [data-wf-bgvideo-fallback-img] { position: absolute; z-index: -100; display: inline-block; height: 100%; width: 100%; object-fit: cover; } }

We want to change how biomarkers are routinely used in oncology

Analyze
the Past

Analyzing
complex genomic
and clinical data

Decode
the present

Decoding biomarkers before,
during or after therapies
using different biopsy-based approaches

Reveal
the future

Revealing innovative tests of
high analytical complexity,
but easy-to-interpret results

Learn more

Treatment optimization

THE FIRST GENOMIC TOOL FOR PATIENTS WITH HER2+ BREAST CANCER
PRECISION ON THE DECISIONS

The first genomic tool for patients with
HER2+ breast cancer

HER2DX^® is intended to help select the optimal treatment strategy for patients.

REVEAL GENOMICS^®and HER2DX^®are registered trademarks of REVEAL GENOMICS S.L.

Learn More Order HER2DX^®

PRESS RELEASE

REVEAL GENOMICS® anuncia la inclusión de su test HER2DX® en las guías clinicas SEOM para cáncer de mama HER2+ en estadios iniciales

NEWS

REVEAL GENOMICS, Dana-Farber Using HER2DX to Analyze Data in Three Breast Cancer Trials

BLOG

We continue to gather more support data for HER2DX®

WORKSHOPPOST-ESMO BREAST CANCER 2023

Learn how HER2DX® can help you apply precision oncology in your clinical practice

Redefining precision oncology

Unlocking the full potential of patient information

We want to change how biomarkers are routinely used in oncology

Analyze the Past

Decode the present

Reveal the future